Provided by Tiger Trade Technology Pte. Ltd.

Rapport Therapeutics, Inc.

32.17
-0.6600-2.01%
Post-market: 31.74-0.4300-1.34%19:59 EDT
Volume:277.63K
Turnover:8.94M
Market Cap:1.54B
PE:-10.54
High:34.48
Open:33.33
Low:31.77
Close:32.83
52wk High:52.93
52wk Low:23.75
Shares:47.98M
Float Shares:30.39M
Volume Ratio:0.50
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0525
EPS(LYR):-2.8633
ROE:-39.96%
ROA:-25.78%
PB:3.65
PE(LYR):-11.24

Loading ...

Rapport Therapeutics management to meet with Citizens

TIPRANKS
·
Jul 16

4x P B For Rapport Therapeutics (RAPP) After Russell Index Additions Looks Pricey

Simply Wall St.
·
Jul 06

Rapport Therapeutics CEO Abraham Ceesay Disposes of Common Shares Worth $327,031.55

Reuters
·
Jul 02

Does Truist’s New RAPP Coverage Subtly Reframe Rapport Therapeutics’ Long-Term Credibility Story (RAPP)?

Simply Wall St.
·
Jun 26

1 Reason Rapport Therapeutics (RAPP) Looks Pricey Following Truist Buy Coverage

Simply Wall St.
·
Jun 25

Rapport Therapeutics Initiated at Outperform by Leerink Partners

Dow Jones
·
Jun 25

Leerink Partners Initiates Rapport Therapeutics at Outperform With $52 Price Target

MT Newswires Live
·
Jun 24

Rapport Therapeutics initiated with an Outperform at Leerink

TIPRANKS
·
Jun 24

Rapport Therapeutics Inc : Leerink Partners Initiates Coverage with Outperform Rating; Price Target $52

THOMSON REUTERS
·
Jun 24

Rapport Therapeutics Holds 2026 Annual Shareholder Meeting

TIPRANKS
·
Jun 11

Rapport Therapeutics shareholders elected Class II directors at annual meeting

Reuters
·
Jun 11

Rapport Therapeutics (RAPP) Is Down 9% After Strong RAP-219 Data Outshines Rival Trial - Has The Bull Case Changed?

Simply Wall St.
·
Jun 06

RAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal Epilepsy

TIPRANKS
·
Jun 05

BTIG Reaffirms Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)

TIPRANKS
·
Jun 02

Third Rock Ventures V disposes of Rapport Therapeutics common shares worth $743,673.08

Reuters
·
May 29

Rapport Therapeutics, Inc. (RAPP) Receives a Buy from BTIG

TIPRANKS
·
May 21

Rapport Therapeutics Is Maintained at Buy by BTIG

Dow Jones
·
May 21

Rapport Therapeutics to present at Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 21

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

GlobeNewswire
·
May 21

Rapport Therapeutics Coverage Assumed by Truist Securities at Buy

Dow Jones
·
May 20